Vol 3, No 1 (2026)

Antibody-drug conjugates are a class of drugs designed to deliver highly effective cytostatic agents directly to tumor cells, thereby reducing their systemic effects and associated toxicity. One representative of this class is datopotamab deruxtecan (Dato-DXd), which is a conjugate of a monoclonal antibody with a cytostatic agent (topoisomerase I inhibitor) targeting trophoblast cell surface antigen 2 – a receptor widely expressed in non-small cell lung cancer, breast cancer and other solid tumors. Dato-DXd was first approved in Japan at the end of 2024 and then in the Russian Federation at the beginning of 2025. As is well known, the key to the successful use of any innovative drug is knowledge of its safety profile and management of adverse events. In this review, we present data on AEs observed in clinical trials of Dato-DXd, necessary preventive measures, and current recommendations for their diagnosis and treatment.

Aim. То compare the safety of use and the analgesic effect of postoperative anesthesia regimens using non-steroidal anti-inflammatory drug (NSAID) – Intrafen-GEN (ibuprofen) with a scheme of postoperative anesthesia based on narcotic analgesics in oncological patients after thoracoscopic and bone-plastic surgery. To evaluate the possibilities of using a postoperative anesthesia regimen using NSAIDs – Intrafen-GEN (ibuprofen) within the framework of the ERAS protocol (Enhanced Recovery After Surgery).

Materials and methods. A single-center prospective comparative study conducted at the N.N. Trapeznikov Research Institute of Clinical Oncology in 2024–2025 included 98 patients who underwent minimally invasive thoracic and bone-plastic surgery.

Results. Based on the area of surgical intervention, all patients (n=98) were divided first into 2 groups, and then into subgroups A and B, according to the schemes of postoperative anesthesia. The first group included 64 patients. It was divided into subgroups A (n = 34) and B (n = 30). The second group included 34 patients and was also divided into subgroups A and B with an equal number of patients in each of the subgroups (n = 17). Patients in subgroup A received a postoperative pain relief regimen using Intrafen-GEN (ibuprofen), and patients in subgroup B received a regimen using trimeperidine. The first intravenous dose of Intrafen-GEN (ibuprofen) – 800 mg was administered 30 minutes before the end of surgery or immediately upon admission to the intensive care unit, then every 8–12 hours for 3 days. In the case of persistent pain, non-opioid and opioid analgesics were added to the treatment until the pain completely disappeared. Patients in subgroup B received anesthesia with trimeperidine 20 mg intramuscularly every 8 hours for 3 postoperative days. The quality of anesthesia in the postoperative period was assessed using the visual analog scale.

Conclusion. In our study, Intrafen-GEN (ibuprofen) was found to be a safe drug, as no complications or side effects were observed during its use. The pain management regimens based on Intrafen-GEN (ibuprofen) demonstrated the complete elimination of opioid analgesics from postoperative pain management in 24 (70.59 %) patients after thoracoscopic surgeries and in 10 (58.85 %) patients after bone-plastic surgeries. When using Intrafen-GEN (ibuprofen), there are no contraindications for the ERAS protocol and early activation of patients in the ICU.

Radiation therapy is a widely used treatment for head and neck cancer, used alone or in combination with chemotherapy or surgery. Despite its effectiveness, radiation therapy is often associated with undesirable side effects. Some oral complications develop soon after the start of treatment, while others may appear months or even years after completion of therapy. This article presents integrated approaches to managing patients with head and neck tumors that improve treatment outcomes and patient quality of life. Integrative, symptom-based approaches may improve patient outcomes; however, data on their use and impact in real-world clinical practice are still limited.

This article presents preventive and therapeutic measures and provides treatment recommendations.